190 related articles for article (PubMed ID: 26044977)
1. Neuropeptide Receptor Ligands for the Treatment of Schizophrenia: Focus on Neurotensin and Tachykinins.
Griebel G
Curr Pharm Des; 2015; 21(26):3807-12. PubMed ID: 26044977
[TBL] [Abstract][Full Text] [Related]
2. Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning?
Griebel G; Holsboer F
Nat Rev Drug Discov; 2012 May; 11(6):462-78. PubMed ID: 22596253
[TBL] [Abstract][Full Text] [Related]
3. Tachykinin receptors as therapeutic targets in stress-related disorders.
Ebner K; Sartori SB; Singewald N
Curr Pharm Des; 2009; 15(14):1647-74. PubMed ID: 19442179
[TBL] [Abstract][Full Text] [Related]
4. Neuropeptide systems and schizophrenia.
LaCrosse AL; Olive MF
CNS Neurol Disord Drug Targets; 2013 Aug; 12(5):619-32. PubMed ID: 23574175
[TBL] [Abstract][Full Text] [Related]
5. Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease.
Mesnage V; Houeto JL; Bonnet AM; Clavier I; Arnulf I; Cattelin F; Le Fur G; Damier P; Welter ML; Agid Y
Clin Neuropharmacol; 2004; 27(3):108-10. PubMed ID: 15190231
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic utility of NK3 receptor antagonists for the treatment of schizophrenia.
Dawson LA; Smith PW
Curr Pharm Des; 2010 Jan; 16(3):344-57. PubMed ID: 20109143
[TBL] [Abstract][Full Text] [Related]
7. Anatomy and mechanisms of neurotensin-dopamine interactions in the central nervous system.
Lambert PD; Gross R; Nemeroff CB; Kilts CD
Ann N Y Acad Sci; 1995 May; 757():377-89. PubMed ID: 7611695
[No Abstract] [Full Text] [Related]
8. Novel treatments of schizophrenia: targeting the neurotensin system.
Kinkead B; Nemeroff CB
CNS Neurol Disord Drug Targets; 2006 Apr; 5(2):205-18. PubMed ID: 16611093
[TBL] [Abstract][Full Text] [Related]
9. Tachykinins and tachykinin receptors in bone.
Goto T; Tanaka T
Microsc Res Tech; 2002 Jul; 58(2):91-7. PubMed ID: 12203708
[TBL] [Abstract][Full Text] [Related]
10. Neurotensin receptor agonists and antagonists for schizophrenia.
Richelson E; Fredrickson PA; Boules MM
Am J Psychiatry; 2005 Mar; 162(3):633-4; author reply 635. PubMed ID: 15741499
[No Abstract] [Full Text] [Related]
11. Neurotensin analogs indications for use as potential antipsychotic compounds.
McMahon BM; Boules M; Warrington L; Richelson E
Life Sci; 2002 Jan; 70(10):1101-19. PubMed ID: 11848295
[TBL] [Abstract][Full Text] [Related]
12. Neurotensin agonists: potential in the treatment of schizophrenia.
Boules M; Shaw A; Fredrickson P; Richelson E
CNS Drugs; 2007; 21(1):13-23. PubMed ID: 17190526
[TBL] [Abstract][Full Text] [Related]
13. Neurotensin receptor agonists and antagonists for schizophrenia.
Robertson VB; Wilson MS
Am J Psychiatry; 2005 Mar; 162(3):634; author reply 635. PubMed ID: 15741502
[No Abstract] [Full Text] [Related]
14. The role of neurotensin in the pathophysiology of schizophrenia and the mechanism of action of antipsychotic drugs.
Binder EB; Kinkead B; Owens MJ; Nemeroff CB
Biol Psychiatry; 2001 Dec; 50(11):856-72. PubMed ID: 11743941
[TBL] [Abstract][Full Text] [Related]
15. Neurokinin-receptor antagonists: pharmacological tools and therapeutic drugs.
Longmore J; Hill RG; Hargreaves RJ
Can J Physiol Pharmacol; 1997 Jun; 75(6):612-21. PubMed ID: 9276138
[TBL] [Abstract][Full Text] [Related]
16. Novel NK(3) receptor antagonists for the treatment of schizophrenia and other CNS indications.
Simonsen KB; Juhl K; Steiniger-Brach B; Nielsen SM
Curr Opin Drug Discov Devel; 2010 Jul; 13(4):379-88. PubMed ID: 20597024
[TBL] [Abstract][Full Text] [Related]
17. Neurotensin, schizophrenia, and antipsychotic drug action.
Kinkead B; Nemeroff CB
Int Rev Neurobiol; 2004; 59():327-49. PubMed ID: 15006494
[TBL] [Abstract][Full Text] [Related]
18. The effects of typical and atypical antipsychotic drugs on neurotensin-containing neurons in the central nervous system.
Kinkead B; Nemeroff CB
J Clin Psychiatry; 1994 Sep; 55 Suppl B():30-2. PubMed ID: 7961568
[TBL] [Abstract][Full Text] [Related]
19. Facilitatory effects of selective agonists for tachykinin receptors on cholinergic neurotransmission: evidence for species differences.
Belvisi MG; Patacchini R; Barnes PJ; Maggi CA
Br J Pharmacol; 1994 Jan; 111(1):103-10. PubMed ID: 7516799
[TBL] [Abstract][Full Text] [Related]
20. Functional and molecular characterization of tachykinins and tachykinin receptors in the mouse uterus.
Patak E; Pinto FM; Story ME; Pintado CO; Fleming A; Page NM; Pennefather JN; Candenas ML
Biol Reprod; 2005 May; 72(5):1125-33. PubMed ID: 15647454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
